- Home
- ACP vs VALN Comparison
ACP vs VALN Comparison
Compare ACP & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACP
- VALN
- Stock Information
- Founded
- ACP 2010
- VALN 2012
- Country
- ACP United States
- VALN France
- Employees
- ACP N/A
- VALN N/A
- Industry
- ACP Investment Managers
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACP Finance
- VALN Health Care
- Exchange
- ACP Nasdaq
- VALN Nasdaq
- Market Cap
- ACP 336.6M
- VALN 378.3M
- IPO Year
- ACP N/A
- VALN 2021
- Fundamental
- Price
- ACP $6.42
- VALN $4.43
- Analyst Decision
- ACP
- VALN Strong Buy
- Analyst Count
- ACP 0
- VALN 2
- Target Price
- ACP N/A
- VALN $18.50
- AVG Volume (30 Days)
- ACP 337.9K
- VALN 24.4K
- Earning Date
- ACP 01-01-0001
- VALN 11-07-2024
- Dividend Yield
- ACP 17.79%
- VALN N/A
- EPS Growth
- ACP N/A
- VALN N/A
- EPS
- ACP N/A
- VALN N/A
- Revenue
- ACP N/A
- VALN $176,817,979.00
- Revenue This Year
- ACP N/A
- VALN $24.30
- Revenue Next Year
- ACP N/A
- VALN $16.05
- P/E Ratio
- ACP N/A
- VALN N/A
- Revenue Growth
- ACP N/A
- VALN N/A
- 52 Week Low
- ACP $5.55
- VALN $4.27
- 52 Week High
- ACP $7.17
- VALN $11.96
- Technical
- Relative Strength Index (RSI)
- ACP 38.79
- VALN 26.35
- Support Level
- ACP $6.39
- VALN $4.27
- Resistance Level
- ACP $6.56
- VALN $4.73
- Average True Range (ATR)
- ACP 0.06
- VALN 0.21
- MACD
- ACP -0.01
- VALN -0.07
- Stochastic Oscillator
- ACP 7.89
- VALN 10.09
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.